-
BFH772 (VEGFR2 Inhibitor): Product Overview
2026-10-09
BFH772 (SKU B6199) is cataloged by APExBIO as a small-molecule VEGFR2 inhibitor. No matched paper evidence was supplied, so potency, selectivity, model activity, and clinical relevance remain supplier-reported claims rather than independently verified findings.
-
Oleanolic Acid, FXR, and Cholestatic Liver Injury
2026-10-09
A 2024 Journal of Applied Toxicology study connects oleanolic acid exposure with impaired bile acid efflux, reduced hepatocyte tight-junction integrity, and altered FXR-regulated transporter activity. Its combined animal, cell, transport, and pharmacological evidence supports a mechanistic model of cholestatic injury while leaving important questions about dose relevance, compound specificity, and human translation.
-
Camostat Mesilate: Evidence and Research Context
2026-10-08
A source-grounded overview of Camostat Mesilate as a trypsin-like protease inhibitor, covering ENaC, plasmin–TGF-β, hepatic fibrosis, evidence quality, and the distinction between protease research and unrelated SARS-CoV-2 PPI studies.
-
Whole-Blood Immunometabolism: Study Evidence
2026-10-08
The Phenomics protocol presents a standardized whole-blood stimulation framework for examining how metabolic interventions shape human immune responses and cytokine production. Its main contribution is methodological: it combines physiologically complex blood samples, defined immune stimuli, pathway-directed metabolic modulation, and quantitative cytokine readouts while clearly defining the evidence boundaries of the platform.
-
Cholecystokinin Octapeptide Ammonium: Evidence Overview
2026-10-07
A source-grounded overview of CCK-8 ammonium covering its brain–gut peptide context, published analgesia findings, proposed receptor biology, conceptual research applications, evidence strength, and key limitations.
-
Surfactant-Derived LNPs for Macrophage mRNA Delivery
2026-10-07
Huang and colleagues developed a dual-component lipid nanoparticle platform based on a surfactant-derived ionizable lipid and a fusogenic lipid for intracellular mRNA delivery to macrophages. The study supports a simpler, PEGylated-lipid-free design with reported nuclease protection, biocompatibility, and activity in hard-to-transfect cells, while remaining limited to preclinical in vitro evidence.
-
Bestatin (Ubenimex): Research Context and Evidence
2026-10-06
Bestatin, also called Ubenimex, is an aminopeptidase inhibitor used as a research tool in protease biology. This overview distinguishes supplier-described properties from peer-reviewed findings, with particular attention to the related compound Phebestin, antiplasmodial research, conceptual applications in cancer and multidrug resistance studies, and the limits of translating enzyme or animal data to human disease.
-
Sodium Salicylate: Evidence, Scope, and Limits
2026-10-05
A source-grounded overview of sodium salicylate and NF-κB signaling, separating supplier claims from direct evidence and explaining why a pancreatic cancer nanomedicine study cannot validate sodium salicylate itself.
-
Ko 143: A Causal Lens on BCRP Efflux
2026-10-05
Ko 143 is a selective BCRP inhibitor for dissecting transporter-driven drug disposition and multidrug resistance. This article develops a causal interpretation framework that separates BCRP-mediated effects from solubility, metabolism, and formulation confounding in cancer and pharmacokinetic research.
-
Aclacinomycin A: DNA Damage Evidence
2026-10-04
Aclacinomycin A, also called Aclarubicin, is a vendor-described anthracycline research compound associated with topoisomerase inhibition, apoptosis signaling, and proteasome activity. Current evidence supports a cautious distinction between compound-specific product claims and direct findings from related studies of topological stress and ribosomal-DNA damage.
-
Silybin A: Reading the Evidence Correctly
2026-10-03
Silymarin research often combines chemically distinct flavonolignans under one label. This evidence-centered guide explains how Silybin A identity, stereochemistry, mechanism, and model context shape interpretation in liver and inflammation research.
-
ERK5 and Vitamin D–Driven Myeloid Differentiation
2026-10-02
Wang and colleagues showed that ERK5 and ERK1/2 make distinct contributions to 1α,25-dihydroxyvitamin D3-induced differentiation of HL60 and U937 myeloid leukemia cells. Their results connect ERK5 inhibition with cell-cycle arrest and altered differentiation-marker expression, while reinforcing that pharmacologic suppression of ERK1/2 broadly weakens the differentiation response.
-
Palmitic acid (N2456): Protocol and QC Guide
2026-10-01
Palmitic acid (hexadecanoic acid, SKU N2456) provides a defined saturated long-chain fatty acid input for solvent-based studies of lipid metabolism, insulin signaling, inflammation, and related metabolic disorder research. It is water-insoluble, so it should not be selected for direct aqueous dissolution or long-term storage of prepared solutions.
-
ARCA Cy5 EGFP mRNA (5-moUTP): Practical Guide
2026-10-01
ARCA Cy5 EGFP mRNA (5-moUTP) provides separate readouts for delivered mRNA and EGFP production, supporting delivery, localization, and translation studies in mammalian cells. It is intended for controlled in vitro workflows, not as evidence of therapeutic performance or a substitute for independently validated paper data.
-
Palmitic acid: Protocol and QC Guide
2026-09-30
Palmitic acid (SKU N2456) provides a defined hexadecanoic acid input for solvent-based workflows in lipid metabolism, metabolic disorder research, and related signaling assays. It is insoluble in water, should not be used in aqueous-only protocols without a validated delivery system, and should not be kept as a long-term solution.